Oracle Corp. (NASDAQ: ORCL) announced today that it has agreed to acquire Phase Forward (NASDAQ: PFWD), a leading provider of applications for life sciences companies and healthcare providers. The deal will take place through a cash merger for $17.00 per share, valued at almost $700 million. Deployed in over 10,000 clinical trials, Phase Forward’s software has been used successfully by hundreds of customers to accelerate innovation in drug development and patient care delivery. (more…)
Follow Us